Dr. David Andes is a faculty member and chief of the Division of Infectious Disease within the Department of Medicine, and also has an appointment in the Department of Medical Microbiology and Immunology. He holds the William A. Craig Endowed Professorship, and directs the Wisconsin Antimicrobial Drug Discovery and Development NIH Center of Excellence.
Dr. Andes is frequently acknowledged for his research contributions in the areas of infectious disease and drug resistance. He has received a National Institutes of Health Mentored Clinical Scientist Development Award, an American Society for Microbiology ICAAC Young Investigator Award, a University of Missouri Alumni Award, a University of Wisconsin Department of Medicine Puestow Research Award and Rankin Research Award, and the Billy Cooper Award from the Medical Mycological Society of the Americas.
Dr. Andes is a Fellow of the Infectious Diseases Society of America and the American Academy of Microbiology. He is the past president of the International Society of Antimicrobial Pharmacology, and has been selected as a member of the American Society of Clinical Investigation, the Clinical Laboratory Standards Institute Antifungal Committee, USCAST, Faculty of 1000, the Mycoses Study Group (MSG) Steering Committee, and the American Association of Physicians. He is an editor of Antimicrobial Agents and Chemotherapy and is on the editorial boards of seven prominent journals. He is a permanent study member for the NIH.
Dr. Andes’ research programs are multidisciplinary and strive to identify strategies to combat antimicrobial (especially antifungal) drug resistance. His study tactics span from the bench to the clinic, including identifying new resistance mechanisms, defining new antimicrobial drug targets, delineating the optimal dosing strategies for treatment of drug resistant infections, and clinical trial study of epidemiology of drug resistance epidemiology. Dr. Andes’ research efforts have been continuously funded by the NIH since 2001. He has published his research in more than 290 papers, which have been cited more than 35,000 times by other scientists. His publications provide much of the scientific underpinning for treatment of drug-resistant infections. The results of these studies have been translated into management guidelines and his scientific approaches are being utilized to identify and develop the next generation of antimicrobial drugs.